Financials data is unavailable for this security.
View more
Year on year Windlas Biotech Ltd grew revenues 22.97% from 5.13bn to 6.31bn while net income improved 36.51% from 426.26m to 581.87m.
| Gross margin | 37.39% |
|---|---|
| Net profit margin | 9.01% |
| Operating margin | 9.90% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Windlas Biotech Ltd increased its cash reserves by 43.46%, or 16.02m. The company earned 1.09bn from its operations for a Cash Flow Margin of 17.27%. In addition the company used 920.68m on investing activities and also paid 152.90m in financing cash flows.
| Cash flow per share | 36.41 |
|---|---|
| Price/Cash flow per share | 23.63 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 37.50% and 41.50%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
| Div yield(5 year avg) | 0.91% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 19.19% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 35.89 |
More ▼
